1-17 of 17
Manish R. Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S. Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron R. Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh Lauring, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3592–3602.
https://doi.org/10.1158/1078-0432.CCR-23-0092
Published: 15 September 2023
View article titled, Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Open the PDF for Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, Rafael D. White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David Jenkins, Andrew Mortlock, Alessandra Forcina, Veerendra Munugalavadla, Ian Flinn
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3301–3312.
https://doi.org/10.1158/1078-0432.CCR-22-2483
Published: 01 September 2023
View article titled, Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Open the PDF for Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment in another window
Includes: Supplementary data
Journal Articles

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4871–4884.
https://doi.org/10.1158/1078-0432.CCR-22-0612
Published: 14 November 2022
View article titled, Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Open the PDF for Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2196.
https://doi.org/10.1158/1078-0432.CCR-22-1108
Published: 13 May 2022
View article titled, Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors
Open the PDF for Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors in another window
Journal Articles

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1540–1548.
https://doi.org/10.1158/1078-0432.CCR-21-2972
Published: 14 April 2022
View article titled, Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Open the PDF for Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1294–1301.
https://doi.org/10.1158/1078-0432.CCR-21-3261
Published: 01 April 2022
View article titled, Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
Open the PDF for Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study in another window
Includes: Supplementary data
Journal Articles

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1302–1312.
https://doi.org/10.1158/1078-0432.CCR-21-3597
Published: 01 April 2022
View article titled, Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors
Open the PDF for Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View article titled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View article titled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em>
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em> in another window
Journal Articles

Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1864–1874.
https://doi.org/10.1158/1078-0432.CCR-20-3242
Published: 01 April 2021
View article titled, Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
Open the PDF for Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor in another window
Includes: Supplementary data
Journal Articles

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 447–459.
https://doi.org/10.1158/1078-0432.CCR-20-2657
Published: 19 January 2021
View article titled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers
Open the PDF for Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A. Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-19-3239
Published: 15 July 2020
View article titled, Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Open the PDF for Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O'Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda Merchant, Gayle Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris Sachsenmeier
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2176–2187.
https://doi.org/10.1158/1078-0432.CCR-19-2183
Published: 01 May 2020
View article titled, Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Open the PDF for Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler, Cristina Saura, Donald A. Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bedard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, Alison K. Cardenas, Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4380–4387.
https://doi.org/10.1158/1078-0432.CCR-18-0613
Published: 14 September 2018
View article titled, Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Open the PDF for Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

Erika P. Hamilton, Manish R. Patel, Anne C. Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah R. Morgan, Gaia Schiavon, Hazel M. Weir, Seock-Ah Im
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3510–3518.
https://doi.org/10.1158/1078-0432.CCR-17-3102
Published: 31 July 2018
View article titled, A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
Open the PDF for A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1525–1535.
https://doi.org/10.1158/1078-0432.CCR-17-2451
Published: 02 April 2018
View article titled, A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors in another window
Journal Articles

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmaña, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Montes, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, Ronnie Shapira-Frommer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4095–4106.
https://doi.org/10.1158/1078-0432.CCR-16-2796
Published: 01 August 2017
View article titled, A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <em>BRCA1/2</em>-Mutated Ovarian Carcinoma or Other Solid Tumors
Open the PDF for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <em>BRCA1/2</em>-Mutated Ovarian Carcinoma or Other Solid Tumors in another window
Includes: Supplementary data